Articles On Patrys (ASX:PAB)

Stockhead’s In-Case-You-Missed-It highlights some of the strongest-performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentag...

Patry receives positive toxicology reports on PAT-DX1 Immutep says triple combination trial of Efti shows it is well tolerated Clarity Pharma is now advancing to cohort 2   Patrys receives positive report Therapeutic antibody development...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

ASX sinks to -0.4% before slogging its way back to -0.22% for the day. Tech stocks were all over the shop but came out on top with +1.2%. Wildcat (ASX:WC8) was King of the Small Caps, adding 34.5% on no fresh news.   After sinking as low...

ASX falls 0.17% ahead of Chalmers dropping The Budget on the nation Financials led the pack today, adding 0.5% on an otherwise fairly moribund day Voltaic Strategic Resources climbs 188% on pre-assay lithium results at Ti Tree   The ASX h...

The S&P ASX 200 finished up 1.85% in April while mid and small caps outperformed their blue-chip peers Real estate topped the winning sectors for the month while tech stocks also rallied strongly in April Gold stocks continued solid ru...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Stable commodity prices and mining stocks saw the ASX break its seven-week losing streak. The ASX 200 is up 2 per cent this year so far after adding 55 points today. All but one of the 11 sectors were in the green, with materials lead...

ASX closes up 0.78%, while XEC rises 1.91% following global markets higher Morningstar warns of possible start of US recession next week spanning 3 quarters, but talk of pause in Aussie rate hikes ‘premature’ Hubify subsidiary Broadland So...

As the first quarter of this calendar year wraps up, Sayona Mining (SYA) and Piedmont Lithium (PLL) have restarted the North American lithium project in Quebec, Canada. Re-start operations were first announced in 2021 and since then, the...

Patrys (PAB) shares are slumping on Friday after the company flagged delays over the phase one clinical trial of its PAT-DX1 compound PAB CEO and Managing Director James Campbell says it is “disappointing” to push back the trial for its...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Australian therapeutic antibody development company Patrys (ASX:PAB) has announced results from a recently completed pre-clinical study that it says validates the potential to use its full-size IgG deoxymab, PATDX3, for synthetic le...

ShareCafeASX falls 1.4% to three-month low by Peter Milios   At the closing bell, the S&P/ASX 200 was 1.4 per cent lower at 7,008.9, a three-month low. The fall was mainly due to concerns about a financial crisis after the collapse of U...

Patrys (PAB) claims a recent pre-clinical study of its PAT-DX3 drug shows the product could treat cancer through “synthetic lethality” strategies The company says its drug platform is designed to cause DNA damage to certain tumours to ul...

ShareCafeASX down 1.91% at noon to lowest point since Jan by Peter Milios   Earlier today, the S&P/ASX 200 stock index of Australia experienced a decline of 2.1 per cent and hit a new low of 6956.7, which is close to its lowest point of...

14 Mar 2023 - A snapshot of the stocks on the move featuring Patrys (ASX:PAB), Mt Monger Resources (ASX:MTM) and Immutep (ASX:IMM).

ShareCafeStocks of the Hour: PAB, MTM, IMM                    Patrys (ASX:PAB) has announced that their preclinical data supports synthetic lethality mechanisms to treat relevant cancers. Patrys Chief Executive Officer and Managing Di...

Patrys says pre-clinical data supports its drug’s synthetic lethality mechanism Alterity granted patent in the US Optiscan says 100% of cancer cases were diagnosed correctly using its device   Patrys’ PAT-DX3 shown to have ‘synthetic leth...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Patrys (PAB) subsidiary Nucleus Therapeutics receives a $3.35 million research and development tax incentive refund from the Australian Federal Government The funds are for R&D undertaken during the 2021/2022 financial year Patrys...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Both the ASX 200 and small cap index were in the green today A massive 11 out 11 sectors finished higher let by Utilities Westpac says rising interest rates and cost of living will hit consumers and businesses after Xmas   The ASX 200 was...

ShareCafeWebinar Recap – HPC, PAB, MKR & SRR Catch up on the full presentations form the Hydration Pharmaceutical Company (ASX: HPC), Patrys (ASX: PAB), Manuka Resources (ASX: MKR) & Sarama Resources (ASX: SRR) – Webinar presentati...

ShareCafePatrys (ASX: PAB) – Webinar presentation James Campbell – Managing Director & CEO Patrys is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. Patr...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Nov 16 (Reuters) - Patrys Ltd: * PATRYS APPOINTS DR CHARMAINE GITTLESON AS CHAIRMAN Source text for Eikon: Further company coverage:

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

Patrys (PAB) confirms its PAT-DX3 antibody can cross the blood-brain barrier in healthy animals after receiving new preclinical data for the productA new PAT-DX3 study found the uptake into the brain of the product, per cubic centimetre, wa...

17 Oct 2022 - A snapshot of the stocks on the move featuring Dreadnought Resources (ASX:DRE), Patrys (ASX:PAB) and Strickland Metals (ASX:STK).

ShareCafeGlobal recession fears weigh in: ASX down 1.6% at noon by Lauren Hayes   US stocks closed the previous week lower after a University of Michigan survey showed inflation expectations were increasing. This rattled markets as equities...

ShareCafeStocks of the Hour: DRE, PAB, STK                    Dreadnought Resources (ASX:DRE) announced today that REE mineralised carbonatite intrusions have been confirmed at the C3 and C4 carbonatites. The company has intersected t...

Patrys crosses blood brain barrier in health animals Cynata receives Notice of Acceptance from IP Australia Telix announces collaboration with GE Healthcare Patrys (ASX:PAB) surged 15% this morning after announcing that its full-sized deo...

Therapeutic antibody development company Patrys (ASX:PAB) has announced new preclinical data for its full-sized IgG antibody, PAT-DX3.

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The ASX is set to open much lower on Monday Wall Street plunged on Friday as earnings season starts RBA meeting minutes to be released this week Local shares are set to reverse Friday’s gains and dive lower today. At 8am AEST, the ASX 200...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Oncology company Patrys (PAB) completes specification tests of drug substance from its lead PAT-DX1 product, produced in a recently-completed engineering run The good manufacturing process (GMP) material produced passed all specification r...

Highlights: The ASX 200 benchmark index closed up today (26 August), gaining 0.79% to end the day at 7,104.10 points. Over the last five days, the index is virtually unchanged, but is down 4.57% for the last year to date. Telecom Serv...

The Victorian government awards Patrys (PAB) a $100,000 Victorian Medical Research Acceleration Fund (VMRAF) grant to support research for metastatic breast cancer The grant will go to the Olivia Newton-John Cancer Research Institute (ONJC...

Patrys gets research grant to progress lead drug Next Science gets Canada license   Bad news for IDT Australia Cancer fighter Patrys (ASX: PAB) has received a new $100k research grant to progress lead drug deoxymabs in treating Metastatic...

Therapeutic antibody development company Patrys (ASX:PAB) has announced new pre-clinical data for its lead asset, PAT-DX1, from a study conducted by Professor Terrence Johns of the Telethon Kids Cancer Centre.

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

Patrys (ASX:PAB) has announced that its contract development manufacturing organisation has successfully completed a second engineering run that used an updated purification process to produce large-scale quantities of clinical-grad...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Patrys’ (PAB) Contract Development Manufacturing Organisation (CDMO) has completed the second engineering run for its cancer antibody candidate, PAT-DX1 The engineering run used an updated purification process to produce large-scale quant...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Emerging Companies (XEC) index tumbles 2.8%   Benchmark ASX200 down 7% over five sessions Square Inc is leaking   Small caps have been hit hard for the second consecutive day – down 2.8% and some 11% over the last five sessions. The ben...

Patrys (PAB) sees a range of PAT-DX1 studies published in peer-reviewed journal ImmunoHorizons supporting its use in treating certain cancers and inflammatory diseases Recent studies have shown neutrophil extracellular traps (NETs) play a...